All you need to know about Prozac

Company Eli Lilly, Prozac manufacturer, doesn’t recommend those people who take monoamine oxidase inhibitors, pimozide (Orap) or thioridazine (Mellaril) to use Prozac . Patients having liver impairment should tell their health care professional about that fact because the elimination of Prozac and its metabolite norfluoxetine is about twice slower in these patients. It induces about double amplification of Prozac exposure. Significant intestinal bleeding can be result of combination of Ibuprofen with Prozac after a period of use.

Nausea (22% vs 9% for placebo), insomnia (19% vs 10% for placebo), somnolence (12% vs 5% for placebo), anorexia (10% vs 3% for placebo), anxiety (12% vs 6% for placebo), nervousness (13% vs 8% for placebo), asthenia (11% vs 6% for placebo) and tremor (9% vs 2% for placebo)are the common adverse effects caused with Prozac and greatly differing from placebo therapy.

7% of patients taking Prozac in clinical trials reported about rash or urticaria, sometimes serious. Discontinuation of the Prozac therapy leaded to that side effect in 32% of those patients. There are some reports about several cases of complications developed in patients with rash. Vasculitis and lupus-like syndrome were observed in those cases. Those systemic events gave occasion to death.

Akathisia is a common side effect of Prozac . It is often accompanied by purposeless movements of the feet and legs, constant pacing, and marked anxiety. Akathisia usually appears after the beginning of the Prozac therapy or increase of the dose. Reducing of Prozac dose, discontinuation of drug or treatment with propranolol can remove or relieve akathisia symptoms. There are proves that akathisia and suicidal attempts are relative. It was reported that there were patients who had been feeling better after the withdrawal of Prozac , but relapsed severe akathisia symptoms after resumption of Prozac therapy. The development of the akathisia forced those patients to wish to make quietus and that it had brought back about their prior suicide attempts. Physician should describe symptoms of akathisia to patients and staff because of coupling of akathisia with suicide and the distress. More rarely, Prozac can cause side effects related with movement disorders such as acute dystonia and tardive dyskinesia.

Increase of rate of poor adaptation of newborns can be resulted with taking Prozac during pregnancy. Mothers having Prozac therapy shouldn’t breastfeed because Prozac was found in milk. Prozac is classified by the American Association of Pediatrics as a drug for which the effect on the breastfeeding baby is still unknown but may be of great importance.

Cooperation between Bryan Molloy and Robert Rathbun in 1970 at leaded to utility invention of Prozac.

Antihistamine diphenhydramine showed some antidepressant-like properties. That fact was known at that time. These scientists chose 3-phenoxy-3-phenylpropylamine (a compound structurally similar to diphenhydramine) as terminus a quo. Dozens of its derivatives have been synthesized by Molloy. A selective norepinephrine reuptake inhibitor Nisoxetine became a result of proving the physiological effects of those agents in mice.

Another Eli Lilly scientist, David Wong, trying to discover a derivative inhibiting only serotonin reuptake, suggested that series of laboratory researches dedicated to reuptake of serotonin, norepinephrine and dopamine should be prospected again. In May 1972 Jong-Sir Horng carrying out that test discovered agent which was named later Prozac. It acted as the most potent and effective selective inhibitor of serotonin reuptake of the series.

Lilly scientists claimed Prozac to be the first selective serotonin reuptake inhibitor (SSRI). But they had to issue a correction two years later,where they declared that zimelidine developed by Arvid Carlsson and colleagues had been the first SSRI.

In August 2001 Prozac patent of Eli Lilly expired that induced inflow of generic drugs onto the market. Eli Lilly rebranded Prozac as “Sarafem” for the treatment of premenstrual dysphoric disorder in attempt to reimburse loss caused with reduction of sales of Prozac in Eli Lilly.